CACNA1I

CACNA1I encodes CaV3.3, a low-voltage-activated T-type calcium channel whose hallmark slow gating drives rebound burst firing and pacemaker oscillations in GABAergic neurons of the thalamic reticular nucleus, where it is required for normal sleep spindle generation during NREM sleep (PMID:32066662, PMID:26612388). The channel's distinctively slow activation and inactivation kinetics are not assigned to any single structural element but emerge from multiple distributed domains, with domain IV serving as the major determinant of activation time constant and recovery from inactivation, and domains I and IV jointly setting the half-activation potential (PMID:15016809, PMID:16996222); alternative splicing of exons 9 and 33 further tunes these gating properties (PMID:15254077). A sustained window current generated by CaV3.3 acts as the critical trigger for spontaneous membrane potential and intracellular Ca2+ oscillations, and genetic deletion of CaV3.3 abolishes low-threshold Ca2+ currents and bursting in reticular thalamic neurons and suppresses sleep-spindle sigma-band EEG power (PMID:16706840, PMID:26612388). Channel activity is negatively regulated by Gaq/11-coupled muscarinic receptors (M1/M3/M5) and by endogenous polyunsaturated lipids that compete with synthetic T-channel inhibitors at a shared binding site (PMID:17535809, PMID:24214826), while surface expression is controlled by neuritin acting through insulin receptor and MEK/ERK signaling (PMID:28475719) and channel gene expression by TET1-mediated DNA hydroxymethylation (PMID:36370755). Disease-causing variants act bidirectionally: gain-of-function substitutions at the cytoplasmic ends of S5/S6 segments and at the channel gate slow gating, left-shift voltage dependence, and increase window current and neuronal excitability, causing neurodevelopmental disorders and seizures, whereas loss-of-function variants reduce current density and excitability (PMID:27756899, PMID:33704440, PMID:40825030).

1. 2003 Medium

   Establishing where and when the CaV3.3 protein is expressed was a prerequisite for assigning physiological function, and protein-level detection showed region- and developmental-stage-specific isoforms.

   Evidence Affinity-purified antibody western blotting and immunohistochemistry across mouse, rat, and human brain and spinal cord at multiple developmental stages

   PMID:12614673

   Open questions at the time

   • Did not resolve molecular basis of the isoform mass differences
   • No functional consequence of differential expression established
2. 2004 Medium

   It was unknown what structural features make CaV3.3 gating so slow; chimera and splicing analyses showed the kinetics are encoded by multiple distributed regions rather than a single domain.

   Evidence CaV3.1/CaV3.3 chimeric channels in Xenopus oocytes and splice-variant constructs (exon 9, delta33) by whole-cell patch-clamp

   PMID:15016809 PMID:15254077

   Open questions at the time

   • Did not identify the specific residues responsible
   • Interaction between intracellular regions inferred, not structurally resolved
3. 2006 Medium

   Refining which domains dominate gating, domain IV was identified as the major determinant of activation and recovery kinetics, and the window current was shown to drive autonomous oscillatory activity.

   Evidence Domain-swap chimeras in tsA-201 cells, and whole-cell patch-clamp plus calcium imaging with pharmacological block in NG108-15 cells

   PMID:16706840 PMID:16996222

   Open questions at the time

   • Domain contributions only partially transfer kinetics
   • Oscillation mechanism characterized in a cell line, not native neurons
4. 2007 High

   How CaV3.3 is acutely modulated and post-translationally processed was unknown; muscarinic Gaq/11 signaling was shown to selectively inhibit CaV3.3, and N-glycosylation/polysialylation was shown to account for isoform mass differences.

   Evidence Perforated patch-clamp with mAChR subtypes and G-protein antagonists plus chimeric mapping; enzymatic deglycosylation (PNGase F, endoneuraminidase-N) with western blotting

   PMID:17317015 PMID:17535809

   Open questions at the time

   • Downstream effector linking Gaq/11 to channel inhibition not defined
   • Functional role of polysialylation on channel activity untested
5. 2013 Medium

   Whether endogenous ligands modulate CaV3.3 was unclear; polyunsaturated lipids were shown to inhibit the channel at a binding site shared with synthetic T-channel blockers.

   Evidence Patch-clamp electrophysiology and [3H]TTA-A1 radioligand competition binding with multiple lipid structures

   PMID:24214826

   Open questions at the time

   • Binding site not structurally localized
   • Physiological relevance of endogenous lipid inhibition in vivo not shown
6. 2016 High

   The in vivo role of CaV3.3 in thalamic rhythmogenesis was untested; a clinical variant and clean knockouts established that CaV3.3 function is required for reticular thalamic bursting and sleep spindle generation.

   Evidence R1346H biochemistry and patch-clamp with NEURON modeling; CaV3.2 and CaV3.2/CaV3.3 double-KO mice with thalamic slice recording and polysomnographic EEG

   PMID:26612388 PMID:27756899

   Open questions at the time

   • Behavioral/cognitive consequences of spindle loss not fully resolved
   • Did not address gain-of-function disease mechanisms
7. 2017 Medium

   Mechanisms controlling CaV3.3 surface availability were unknown; neuritin was shown to increase channel surface expression via IR and MEK/ERK signaling, linking it to glutamate release.

   Evidence mEPSC recording, membrane-protein western blotting, HPLC, and pharmacological inhibition of IR/MEK/ERK and T-type channels in prefrontal cortex neurons

   PMID:28475719

   Open questions at the time

   • Direct interaction between neuritin/IR and CaV3.3 not demonstrated
   • Trafficking pathway inferred from inhibitor effects
8. 2021 High

   Whether CACNA1I disease variants act by gain or loss of function was unresolved; gain-of-function variants at S5/S6 cytoplasmic ends were shown to slow gating, increase window current, and elevate excitability.

   Evidence Site-directed mutagenesis, patch-clamp in HEK293T, structural modeling, native mouse chromaffin cell expression, and computational TRN modeling

   PMID:33704440

   Open questions at the time

   • No in vivo model of the gain-of-function variants
   • Structural basis of gating slowing inferred from modeling
9. 2022 Medium

   Additional disease and regulatory contexts were tested: rare variants alter biophysics in hemiplegic migraine, and TET1-mediated DNA hydroxymethylation controls Cav3.3 transcription.

   Evidence Patch-clamp of variant channels in HEK293T; TET1 overexpression/knockdown with MeDIP/hMeDIP and viability assays in Leydig cells

   PMID:35928792 PMID:36370755

   Open questions at the time

   • Causality of migraine variants not established beyond biophysics
   • TET1 regulation shown in a non-neuronal cell line
10. 2025 High

    Whether the same residue can yield opposite functional outcomes was unknown; paired substitutions at A398 produced gain- versus loss-of-function, correlating seizures with gain-of-function excitability increases.

    Evidence Site-directed mutagenesis, voltage-clamp electrophysiology, and computational and structural modeling

    PMID:40825030

    Open questions at the time

    • Genotype-phenotype correlation based on modeling, not patient-derived neurons
    • No therapeutic intervention tested

• The structural basis for CaV3.3's distributed slow-gating mechanism and the precise molecular link between Gaq/11 or lipid binding and channel inhibition remain undefined.
• No high-resolution structure of the channel or ligand-binding site
• Direct effectors coupling receptor signaling to channel gating unidentified
• In vivo disease models for most variants lacking